M. Meier

From acute injury to chronic disease: pathophysiological hypothesis of an epithelial/mesenchymal crosstalk alteration in CKD.

M. Prunotto, D. Budd, M. Meier, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Targeting the epithelial cells in fibrosis: a new concept for an old disease.

M. Prunotto, D. Budd, M. Meier, 2013, Drug discovery today.

Glucose metabolism in isolated brown adipocytes under beta-adrenergic stimulation. Quantitative contribution of glucose to total thermogenesis.

M. Meier, D. Isler, H. P. Hill, 1987, The Biochemical journal.

Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats

A. Bourson, M. Meier, I. Kunz, 2008, International Journal of Obesity.

The novel thermogenic beta-adrenergic agonist Ro 16-8714 increases the interscapular brown-fat beta-receptor-adenylate cyclase and the uncoupling-protein mRNA level in obese (fa/fa) Zucker rats.

J. Giacobino, F. Assimacopoulos-Jeannet, P. Muzzin, 1989, The Biochemical journal.

Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase.

P. Hadváry, H. Lengsfeld, A. Fleury, 1987, International journal of obesity.

Effect of a β-adrenergic agonist on glucose transport and insulin-responsive glucose transporters (GLUT4) in brown adipose tissue of control and obese fa/fa rats

F. Assimacopoulos-Jeannet, M. Meier, B. Jeanrenaud, 1992, Pflügers Archiv.

Hypoglycemic effects of a beta-agonist, Ro 16-8714, in streptozotocin-diabetic rats: decreased hepatic glucose production and increased glucose utilization in oxidative muscles.

P. Ferré, L. Pénicaud, J. Girard, 1992, Metabolism: clinical and experimental.

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss

S. Jacob, M. Meier, M. Rabbia, 2009, Diabetes, obesity & metabolism.

Epithelial–mesenchymal crosstalk alteration in kidney fibrosis

M. Prunotto, G. Gabbiani, D. Budd, 2012, The Journal of pathology.

Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).

M. Prunotto, C. Haefliger, M. Meier, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

New renal drug development to face chronic renal disease

M. Prunotto, M. Meier, Ivan Formentini, 2014, Expert opinion on drug discovery.

Phenethanolamine derivatives with calorigenic and antidiabetic qualities.

M. Meier, L. Alig, M. E. Bürgi-Saville, 1984, International journal of obesity.